Clinical Trial Detail

NCT ID NCT03971409
Title Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer (InCITe)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hope Rugo, MD
Indications

triple-receptor negative breast cancer

Therapies

Avelumab + PF-04518600

Avelumab + Utomilumab

Avelumab + Binimetinib

Age Groups: adult senior

No variant requirements are available.